Find your next paid study

Revolution Medicines, Inc.NCT07252232

~$50 – $2,100

Actual pay is set by the research site.

Advanced Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage III Pancreatic Cancer AJCC v8+2 more

Phase I/II Study of the MEK Inhibitor Selumetinib Plus DS-8201a (Trastuzumab Deruxtecan) in KRAS-Mutant, HER2-Expressing Pancreatic Ductal Adenocarcinoma

This phase I/II trial tests the safety, side effects, best dose and how well giving selumetinib with trastuzumab deruxtecan (DS-8201a) works for the treatment …

National Cancer Institute (NCI)NCT07619521

~$150 – $2,700

Actual pay is set by the research site.

Advanced Pancreatic AdenocarcinomaStage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8+1 more

A Phase 1b Study of Gemcitabine and Leflunomide in Patients With Unresectable Pancreatic Cancer

This phase Ib trial tests the safety, side effects, and best dose of leflunomide in combination with gemcitabine in treating patients with pancreatic cancer th…

City of Hope Medical CenterNCT06454383

Actual pay is set by the research site.

Borderline Resectable Pancreatic Ductal Adenocarcinoma

DCE-MRI-Informed Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

This clinical trial tests how well dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) with standard clinical evaluation works to assess treatment r…

Ohio State University Comprehensive Cancer CenterNCT07705919

Actual pay is set by the research site.

Borderline Resectable Pancreatic Ductal AdenocarcinomaResectable Pancreatic Ductal Adenocarcinoma

SMART-PANC: SMAD4 Tailored Neoadjuvant Therapy for Pancreatic Cancer, A Phase ll Non-Randomized, Single Center Pilot Study

This phase II trial tests the impact of using SMAD4-mutant status to personalize chemotherapy in treating patients with pancreatic ductal adenocarcinoma (PDAC)…

Northwestern UniversityNCT07748611

~$75 – $2,000

Actual pay is set by the research site.

Resectable Pancreatic Ductal AdenocarcinomaBorderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced Pancreatic Ductal Adenocarcinoma

Phase 1b Window-of-Opportunity Study Evaluating CDK7 Inhibition in Patients With Localized Basal Pancreatic Cancer

The purpose of this study is to evaluate the safety and efficacy of samuraciclib in patients with localized pancreatic cancer.

University of WashingtonNCT07645651

Actual pay is set by the research site.

Borderline Resectable Pancreatic Ductal Adenocarcinoma

A Phase 2 Clinical Trial of Nalirifox as Neoadjuvant Treatment for Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma (Nectar Study)

This phase II trial tests how well liposomal irinotecan, oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) before surgery works in treating patients with …

Roswell Park Cancer InstituteNCT06821997

~$75 – $3,000

Actual pay is set by the research site.

Locally Advanced Pancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage II Pancreatic Cancer AJCC v8+5 more

A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients With Pancreatic Ductal Adenocarcinoma

This early phase I trial aims to determine how cobimetinib, olaparib, onvansertib, azenosertib, AZD5305 or tremelimumab works in patients with pancreatic cance…

OHSU Knight Cancer Institute

~$150 – $4,500

Actual pay is set by the research site.

Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma Patients

This study explores the relationship between pre-treatment dietary patterns, fecal microbiome, and response to chemotherapy in patients with pancreatic ductal …

Borderline Resectable Pancreatic Ductal AdenocarcinomaResectable Pancreatic Ductal AdenocarcinomaStage I Pancreatic Cancer AJCC v8

Emory UniversityNCT06595160

~$10 – $750

Actual pay is set by the research site.

Localized Pancreatic AdenocarcinomaResectable Pancreatic Ductal AdenocarcinomaStage 0 Pancreatic Cancer AJCC v8+2 more

Quantitative In Vivo 68Ga-Fibroblast-Activation-Protein-Inhibitors (FAPI)-46 PET Imaging of Cancer-Associated Fibroblasts (CAFs) in Pancreatic Ductal Adenocarcinoma (PDA)

This phase II trial tests whether 68Ga-FAPI-46 positron emission tomography (PET)/computed tomography (CT) scan works to image cancer-associated fibroblasts (C…

~$75 – $2,000

Actual pay is set by the research site.

Mayo ClinicNCT05518903

Borderline Resectable Pancreatic Ductal AdenocarcinomaResectable Pancreatic AdenocarcinomaStage I Pancreatic Cancer AJCC v8+2 more

A Single-Arm Phase II Clinical Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma

This phase II trial tests how well gemcitabine, cisplatin and nab-paclitaxel given before surgery (neoadjuvant) works in treating patients with pancreatic canc…

Georgetown UniversityNCT06423326

~$75 – $2,000

Actual pay is set by the research site.

Borderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced CholangiocarcinomaLocally Advanced Pancreatic Adenocarcinoma+5 more

A Phase 1/1b Trial of AB801 in Combination With Chemotherapy and PD-1/PD-L1 Blockade in Patients With Cholangiocarcinoma or Pancreatic Adenocarcinoma

This phase I trial tests the safety, side effects, best dose and effectiveness of AB801 in combination with chemotherapy and immunotherapy in treating patients…